Share
The investigational anticoagulation medication apixaban appears to surpass aspirin in prevention of perilous blood clot formations or stroke among individuals suffering from irregular cardiac rhythm atrial fibrillation, as per the concluding outcomes of the so-dubbed AVERROES study.
The late stage phase three trial was halted earlier on following apixaban’s benefits becoming clearer, & preliminary outcomes were firstly cited in Sep. last year.
Recently, presentation of the concluding outcomes was made during the recently held ASA’s International Stroke Conference.
In case apixaban does receive approval, it would provide a substitute to the older stand-by warfarin that several individuals cannot take or are not willing to use.
The trial which appeared on line in ‘The New England Journal of Medicine’ enrolled 5600 atrial fibrillation sufferers among whom the use of warfarin was deemed inappropriate, apixaban reduced risk by over fifty percent in comparison to aspirin.
In every one thousand sufferers given apixaban treatment rather than aspirin for twelve months, twenty-one stroke cases, 9 mortalities & thirty-three hospitalization cases would be averted, according to German Doctor Diener from Univ. of Essen.
But, 2 from one thousand atrial fibrillation sufferers would experience major blood loss, Diener points out while presenting the outcomes of the trial which received the funding Pfizer & Bristol-Myers Squibb. He ecstatically declared that the outcomes of this study have the potential to transform medical practices.
Warfarin Downsides
The trial did a follow-up on people having atrial fibrillation (AF), a problem typified by erratic cardiac rhythms. Most of these sufferers have a greater likelihood of experiencing strokes as compared to individuals not having this condition since their erratic cardiac beats might facilitate blood pooling in the upper heart compartment thus increasing likelihood of clot formations that could then reach the brain & obstruct blood supply leading to stroke.
Warfarin is the regular therapy, however nearly fifty percent of patients are incompatible for it due to augmented chances of blood loss or medication interaction or simply refusal for taking it. In case excess is taken, one could ail from risky bleeding while taking lesser than needed would increase risk of lethal blood clots associated to AF forming. 
Aspiring is the regular option for people who could not use warfarin, however it has lesser efficacy. Hence, there was a hunt for unearthing an able substitute. The medication Pradaxa had lately garnered the FDA nod for this usage. Xarelto, Apixaban have been found to be effectual in later-staging tests, though they still haven’t received acceptance for such usage.
Apixaban belongs to a group of novel medications known as Xa inhibitors which are capable of interfering with the coagulating mechanism of our bodies.
